Evidence map›Paper›PMID 39897292›Full record

ArticleCureus2025

Spontaneous Hepatic Hemorrhage as a Rare Presentation of Amyloid Light Chain (AL) Amyloidosis: A Case Report.

Manjul Srivastava

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Manjul SrivastavaInternal Medicine, Northwest Medical Center, Tucson, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spontaneous hepatic hemorrhage due to amyloidosis light chain (AL) is a rare but serious life-threatening condition. In this case, a 64-year-old male patient presented to the emergency room with acute right shoulder pain. He was recently diagnosed with type 2 diabetes. He did not have any recent trauma, procedures, history of hepatitis, alcoholism, or chronic inflammatory or bleeding disorders. The patient's computed tomography (CT) scan of the abdomen was positive for acute subcapular hematoma. He developed acute nephrotic syndrome within two days of admission. Further workup showed elevated monoclonal lambda light chains and confirmed AL amyloidosis on bone marrow biopsy. This case is unique because subcapsular hepatic hematoma was the only manifestation of AL amyloidosis. While amyloid deposition does occur in systemic amyloidosis, it is exceptionally rare for patients to present with spontaneous hepatic rupture without any prior diagnosis. Recognizing this atypical presentation of AL amyloidosis is crucial for timely intervention and improved outcomes. Familiarity with the rare etiology of intrahepatic hemorrhage may help to decrease the high mortality rate associated with this rare disease. Treatment for hepatic hemorrhage consists of aggressive blood transfusion and CT-guided hepatic artery embolization. Chemotherapy with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) can halt amyloid deposition.

Indexed as

amyloidosis alfactor x deficencyhepatic artery embolizationlight chain amyloidosisspontaneous hepatic subcapsular hematoma

Identifiers

PMID39897292
PMCPMC11786779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.